220 related articles for article (PubMed ID: 17369490)
1. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency.
Chinen J; Davis J; De Ravin SS; Hay BN; Hsu AP; Linton GF; Naumann N; Nomicos EY; Silvin C; Ulrick J; Whiting-Theobald NL; Malech HL; Puck JM
Blood; 2007 Jul; 110(1):67-73. PubMed ID: 17369490
[TBL] [Abstract][Full Text] [Related]
2. Retroviral transduction of IL2RG into CD34(+) cells from X-linked severe combined immunodeficiency patients permits human T- and B-cell development in sheep chimeras.
Tsai EJ; Malech HL; Kirby MR; Hsu AP; Seidel NE; Porada CD; Zanjani ED; Bodine DM; Puck JM
Blood; 2002 Jul; 100(1):72-9. PubMed ID: 12070011
[TBL] [Abstract][Full Text] [Related]
3. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Mamcarz E; Zhou S; Lockey T; Abdelsamed H; Cross SJ; Kang G; Ma Z; Condori J; Dowdy J; Triplett B; Li C; Maron G; Aldave Becerra JC; Church JA; Dokmeci E; Love JT; da Matta Ain AC; van der Watt H; Tang X; Janssen W; Ryu BY; De Ravin SS; Weiss MJ; Youngblood B; Long-Boyle JR; Gottschalk S; Meagher MM; Malech HL; Puck JM; Cowan MJ; Sorrentino BP
N Engl J Med; 2019 Apr; 380(16):1525-1534. PubMed ID: 30995372
[TBL] [Abstract][Full Text] [Related]
5. Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy.
Ting-De Ravin SS; Kennedy DR; Naumann N; Kennedy JS; Choi U; Hartnett BJ; Linton GF; Whiting-Theobald NL; Moore PF; Vernau W; Malech HL; Felsburg PJ
Blood; 2006 Apr; 107(8):3091-7. PubMed ID: 16384923
[TBL] [Abstract][Full Text] [Related]
6. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
[TBL] [Abstract][Full Text] [Related]
7. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Adams S; Howe SJ; Al Ghonaium A; Bayford J; Brown L; Davies EG; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra79. PubMed ID: 21865537
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy studies in a canine model of X-linked severe combined immunodeficiency.
Felsburg PJ; De Ravin SS; Malech HL; Sorrentino BP; Burtner C; Kiem HP
Hum Gene Ther Clin Dev; 2015 Mar; 26(1):50-6. PubMed ID: 25603151
[TBL] [Abstract][Full Text] [Related]
9. Marking of peripheral T-lymphocytes by retroviral transduction and transplantation of CD34+ cells in a canine X-linked severe combined immunodeficiency model.
Suter SE; Gouthro TA; O'Malley T; Hartnett BJ; McSweeney PA; Moore PF; Felsburg PJ; Haskins ME; Henthorn PS
Vet Immunol Immunopathol; 2007 Jun; 117(3-4):183-96. PubMed ID: 17442404
[TBL] [Abstract][Full Text] [Related]
10. Retroviral marking of canine bone marrow: long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes.
Whitwam T; Haskins ME; Henthorn PS; Kraszewski JN; Kleiman SE; Seidel NE; Bodine DM; Puck JM
Blood; 1998 Sep; 92(5):1565-75. PubMed ID: 9716584
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.
De Ravin SS; Wu X; Moir S; Anaya-O'Brien S; Kwatemaa N; Littel P; Theobald N; Choi U; Su L; Marquesen M; Hilligoss D; Lee J; Buckner CM; Zarember KA; O'Connor G; McVicar D; Kuhns D; Throm RE; Zhou S; Notarangelo LD; Hanson IC; Cowan MJ; Kang E; Hadigan C; Meagher M; Gray JT; Sorrentino BP; Malech HL; Kardava L
Sci Transl Med; 2016 Apr; 8(335):335ra57. PubMed ID: 27099176
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma.
Kennedy DR; Hartnett BJ; Kennedy JS; Vernau W; Moore PF; O'Malley T; Burkly LC; Henthorn PS; Felsburg PJ
Vet Immunol Immunopathol; 2011 Jul; 142(1-2):36-48. PubMed ID: 21536334
[TBL] [Abstract][Full Text] [Related]
13. Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.
Huston MW; Riegman AR; Yadak R; van Helsdingen Y; de Boer H; van Til NP; Wagemaker G
Hum Gene Ther; 2014 Oct; 25(10):905-14. PubMed ID: 25222508
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S
Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
[TBL] [Abstract][Full Text] [Related]
16. Lack of dominant-negative effects of a truncated gamma(c) on retroviral-mediated gene correction of immunodeficient mice.
Otsu M; Sugamura K; Candotti F
Blood; 2001 Mar; 97(6):1618-24. PubMed ID: 11238100
[TBL] [Abstract][Full Text] [Related]
17. Keratinocyte antiviral response to Poly(dA:dT) stimulation and papillomavirus infection in a canine model of X-linked severe combined immunodeficiency.
Luff JA; Yuan H; Kennedy D; Schlegel R; Felsburg P; Moore PF
PLoS One; 2014; 9(7):e102033. PubMed ID: 25025687
[TBL] [Abstract][Full Text] [Related]
18. Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1.
Touzot F; Moshous D; Creidy R; Neven B; Frange P; Cros G; Caccavelli L; Blondeau J; Magnani A; Luby JM; Ternaux B; Picard C; Blanche S; Fischer A; Hacein-Bey-Abina S; Cavazzana M
Blood; 2015 Jun; 125(23):3563-9. PubMed ID: 25869287
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency.
Speckmann C; Pannicke U; Wiech E; Schwarz K; Fisch P; Friedrich W; Niehues T; Gilmour K; Buiting K; Schlesier M; Eibel H; Rohr J; Superti-Furga A; Gross-Wieltsch U; Ehl S
Blood; 2008 Nov; 112(10):4090-7. PubMed ID: 18728247
[TBL] [Abstract][Full Text] [Related]
20. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome.
Qazilbash MH; Walsh CE; Russell SM; Noguchi M; Mann MM; Leonard WJ; Liu JM
J Hematother; 1995 Apr; 4(2):91-8. PubMed ID: 7633846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
